Anti-TNF-alpha Therapy Enhances the Effects of Enzyme Replacement Therapy in Rats with Mucopolysaccharidosis Type VI

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Sep 3

PMID 21887218

Citations 39

Authors

Efrat Eliyahu

Theodore Wolfson

Yi Ge

Karl J Jepsen

Edward H Schuchman

Calogera M Simonaro

Affiliations

Soon will be listed here.

Abstract

Background: Although enzyme replacement therapy (ERT) is available for several lysosomal storage disorders, the benefit of this treatment to the skeletal system is very limited. Our previous work has shown the importance of the Toll-like receptor 4/TNF-alpha inflammatory pathway in the skeletal pathology of the mucopolysaccharidoses (MPS), and we therefore undertook a study to examine the additive benefit of combining anti-TNF-alpha therapy with ERT in a rat model of MPS type VI.

Methodology/principal Findings: MPS VI rats were treated for 8 months with Naglazyme® (recombinant human N-acetyl-galactosamine-4-sulfatase), or by a combined protocol using Naglazyme® and the rat-specific anti-TNF-alpha drug, CNTO1081. Both protocols led to markedly reduced serum levels of TNF-alpha and RANKL, although only the combined treatment reduced TNF-alpha in the articular cartilage. Analysis of cultured articular chondrocytes showed that the combination therapy also restored collagen IIA1 expression, and reduced expression of the apoptotic marker, PARP. Motor activity and mobility were improved by ERT, and these were significantly enhanced by combination treatment. Tracheal deformities in the MPS VI animals were only improved by combination therapy, and there was a modest improvement in bone length. Ceramide levels in the trachea also were markedly reduced. MicroCT analysis did not demonstrate any significant positive effects on bone microarchitecture from either treatment, nor was there histological improvement in the bone growth plates.

Conclusions/significance: The results demonstrate that combining ERT with anti-TNF-alpha therapy improved the treatment outcome and led to significant clinical benefit. They also further validate the usefulness of TNF-alpha, RANKL and other inflammatory molecules as biomarkers for the MPS disorders. Further evaluation of this combination approach in other MPS animal models and patients is warranted.

Citing Articles

Endocannabinoid receptor 2 is a potential biomarker and therapeutic target for the lysosomal storage disorders.

Simonaro C, Yasuda M, Schuchman E J Inherit Metab Dis. 2024; 48(1):e12813.

PMID: 39569490 PMC: 11670223. DOI: 10.1002/jimd.12813.

Molecular Mechanisms in Pathophysiology of Mucopolysaccharidosis and Prospects for Innovative Therapy.

Ago Y, Rintz E, Musini K, Ma Z, Tomatsu S Int J Mol Sci. 2024; 25(2).

PMID: 38256186 PMC: 10816168. DOI: 10.3390/ijms25021113.

An Innovative Tool for Evidence-Based, Personalized Treatment Trials in Mucopolysaccharidosis.

Wiesinger A, Bigger B, Giugliani R, Lampe C, Scarpa M, Moser T Pharmaceutics. 2023; 15(5).

PMID: 37242808 PMC: 10221776. DOI: 10.3390/pharmaceutics15051565.

The Interplay of Glycosaminoglycans and Cysteine Cathepsins in Mucopolysaccharidosis.

David A, Chazeirat T, Saidi A, Lalmanach G, Lecaille F Biomedicines. 2023; 11(3).

PMID: 36979788 PMC: 10045161. DOI: 10.3390/biomedicines11030810.

Mucopolysaccharidoses: Cellular Consequences of Glycosaminoglycans Accumulation and Potential Targets.

Leal A, Benincore-Florez E, Rintz E, Herreno-Pachon A, Celik B, Ago Y Int J Mol Sci. 2023; 24(1).

PMID: 36613919 PMC: 9820209. DOI: 10.3390/ijms24010477.

References

Wraith J, Scarpa M, Beck M, Bodamer O, De Meirleir L, Guffon N . Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2007; 167(3):267-77. PMC: 2234442. DOI: 10.1007/s00431-007-0635-4. View

Osborn M, McElmurry R, Lees C, DeFeo A, Chen Z, Kay M . Minicircle DNA-based gene therapy coupled with immune modulation permits long-term expression of α-L-iduronidase in mice with mucopolysaccharidosis type I. Mol Ther. 2010; 19(3):450-60. PMC: 3048178. DOI: 10.1038/mt.2010.249. View

Auclair D, Hopwood J, Lemontt J, Chen L, Byers S . Long-term intra-articular administration of recombinant human N-acetylgalactosamine-4-sulfatase in feline mucopolysaccharidosis VI. Mol Genet Metab. 2007; 91(4):352-61. DOI: 10.1016/j.ymgme.2007.04.009. View

Simonaro C, Ge Y, Eliyahu E, He X, Jepsen K, Schuchman E . Involvement of the Toll-like receptor 4 pathway and use of TNF-alpha antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci U S A. 2009; 107(1):222-7. PMC: 2806747. DOI: 10.1073/pnas.0912937107. View

Cotugno G, Tessitore A, Capalbo A, Annunziata P, Strisciuglio C, Faella A . Different serum enzyme levels are required to rescue the various systemic features of the mucopolysaccharidoses. Hum Gene Ther. 2009; 21(5):555-69. DOI: 10.1089/hum.2009.189. View

Glamuzina E, Fettes E, Bainbridge K, Crook V, Finnegan N, Abulhoul L . Treatment of mucopolysaccharidosis type II (Hunter syndrome) with idursulfase: the relevance of clinical trial end points. J Inherit Metab Dis. 2011; 34(3):749-54. DOI: 10.1007/s10545-011-9280-1. View

Simonaro C, Haskins M, Schuchman E . Articular chondrocytes from animals with a dermatan sulfate storage disease undergo a high rate of apoptosis and release nitric oxide and inflammatory cytokines: a possible mechanism underlying degenerative joint disease in the mucopolysaccharidoses. Lab Invest. 2001; 81(9):1319-28. DOI: 10.1038/labinvest.3780345. View

McGill J, Inwood A, Coman D, Lipke M, de Lore D, Swiedler S . Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age--a sibling control study. Clin Genet. 2009; 77(5):492-8. DOI: 10.1111/j.1399-0004.2009.01324.x. View

Yoshida M, Noguchi J, Ikadai H, Takahashi M, Nagase S . Arylsulfatase B-deficient mucopolysaccharidosis in rats. J Clin Invest. 1993; 91(3):1099-104. PMC: 288065. DOI: 10.1172/JCI116268. View

10.

Connor V . Anti-TNF therapies: a comprehensive analysis of adverse effects associated with immunosuppression. Rheumatol Int. 2009; 31(3):327-37. DOI: 10.1007/s00296-009-1292-x. View

11.

Simonaro C, DAngelo M, Haskins M, Schuchman E . Joint and bone disease in mucopolysaccharidoses VI and VII: identification of new therapeutic targets and biomarkers using animal models. Pediatr Res. 2005; 57(5 Pt 1):701-7. DOI: 10.1203/01.PDR.0000156510.96253.5A. View

12.

Kunieda T, Simonaro C, Yoshida M, Ikadai H, Levan G, Desnick R . Mucopolysaccharidosis type VI in rats: isolation of cDNAs encoding arylsulfatase B, chromosomal localization of the gene, and identification of the mutation. Genomics. 1995; 29(3):582-7. DOI: 10.1006/geno.1995.9962. View

13.

Valayannopoulos V, Nicely H, Harmatz P, Turbeville S . Mucopolysaccharidosis VI. Orphanet J Rare Dis. 2010; 5:5. PMC: 2873242. DOI: 10.1186/1750-1172-5-5. View

14.

Klaasen R, Wijbrandts C, Gerlag D, Tak P . Body mass index and clinical response to infliximab in rheumatoid arthritis. Arthritis Rheum. 2011; 63(2):359-64. DOI: 10.1002/art.30136. View

15.

Simonaro C, DAngelo M, He X, Eliyahu E, Shtraizent N, Haskins M . Mechanism of glycosaminoglycan-mediated bone and joint disease: implications for the mucopolysaccharidoses and other connective tissue diseases. Am J Pathol. 2007; 172(1):112-22. PMC: 2189614. DOI: 10.2353/ajpath.2008.070564. View

16.

Simonaro C, Haskins M, Kunieda T, Evans S, Visser J, Schuchman E . Bone marrow transplantation in newborn rats with mucopolysaccharidosis type VI: biochemical, pathological, and clinical findings. Transplantation. 1997; 63(10):1386-93. DOI: 10.1097/00007890-199705270-00003. View

17.

Rutella S, Fiorino G, Vetrano S, Correale C, Spinelli A, Pagano N . Infliximab therapy inhibits inflammation-induced angiogenesis in the mucosa of patients with Crohn's disease. Am J Gastroenterol. 2011; 106(4):762-70. DOI: 10.1038/ajg.2011.48. View

18.

Becker K, Tummler B, Gulbins E, Grassme H . Accumulation of ceramide in the trachea and intestine of cystic fibrosis mice causes inflammation and cell death. Biochem Biophys Res Commun. 2010; 403(3-4):368-74. DOI: 10.1016/j.bbrc.2010.11.038. View

19.

Cox-Brinkman J, van den Bergh Weerman M, Wijburg F, Aerts J, Florquin S, van der Lee J . Ultrastructural analysis of dermal fibroblasts in mucopolysaccharidosis type I: Effects of enzyme replacement therapy and hematopoietic cell transplantation. Ultrastruct Pathol. 2010; 34(3):126-32. DOI: 10.3109/01913121003648485. View

20.

Decker C, Yu Z, Giugliani R, Schwartz I, Guffon N, Leao Teles E . Enzyme replacement therapy for mucopolysaccharidosis VI: Growth and pubertal development in patients treated with recombinant human N-acetylgalactosamine 4-sulfatase. J Pediatr Rehabil Med. 2010; 3(2):89-100. PMC: 2904323. DOI: 10.3233/PRM-2010-0113. View